JY
CARM

Jeff Yass’s Carisma Therapeutics CARM Stock Holding History

Jeff Yass’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,800
Closed -$118K – 12404
2023
Q3 		$118K Hold
27,800
– – ﹤0.01% 10784
2023
Q2 		$244K Sell
27,800
-66,800
-71% -$364K ﹤0.01% 9857
2023
Q1 		$293K Buy
94,600
+63,640
+206% +$606K ﹤0.01% 9778
2022
Q4 		$378K Sell
30,960
-1,820
-6% -$19.1K ﹤0.01% 8538
2022
Q3 		$282K Sell
32,780
-180
-0.5% -$2.45K ﹤0.01% 9946
2022
Q2 		$534K Sell
32,960
-1,480
-4% -$16.9K ﹤0.01% 8095
2022
Q1 		$413K Sell
34,440
-19,820
-37% -$277K ﹤0.01% 9463
2021
Q4 		$890K Buy
54,260
+11,105
+26% +$224K ﹤0.01% 7593
2021
Q3 		$685K Buy
43,155
+20,915
+94% +$1M ﹤0.01% 8571
2021
Q2 		$2.06M Sell
22,240
-9,870
-31% -$629K ﹤0.01% 5857
2021
Q1 		$1.67M Buy
32,110
+28,290
+741% +$1.33M ﹤0.01% 6356
2020
Q4 		$103K Buy
3,820
+3,210
+526% +$81.4K ﹤0.01% 10475
2020
Q3 		$17K Sell
610
-445
-42% -$8.9K ﹤0.01% 10386
2020
Q2 		$15K Sell
1,055
-7,165
-87% -$96.6K ﹤0.01% 9947
2020
Q1 		$92K Buy
8,220
+500
+6% +$8.19K ﹤0.01% 9375
2019
Q4 		$161K Buy
7,720
+1,165
+18% +$26.8K ﹤0.01% 8902
2019
Q3 		$153K Buy
6,555
+4,585
+233% +$107K ﹤0.01% 9309
2019
Q2 		$59K Buy
+1,970
New +$59K ﹤0.01% 9802
2018
Q4 		– Sell
-5,185
Closed -$223K – 8977
2018
Q3 		$223K Sell
5,185
-3,835
-43% -$149K ﹤0.01% 8019
2018
Q2 		$352K Buy
+9,020
New +$397K ﹤0.01% 7521
2017
Q2 		– Sell
-580
Closed -$26K – 9220
2017
Q1 		$26K Sell
580
-5
-0.9% -$208 ﹤0.01% 8691
2016
Q4 		$22K Sell
585
-565
-49% -$24.9K ﹤0.01% 9420
2016
Q3 		$64K Buy
+1,150
New +$85.6K ﹤0.01% 8065

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jeff Yass's CARM Position: Q3 2024 in Review

Jeff Yass sold out of Carisma Therapeutics (CARM) in Q3 2024, closing a stake of 73,323 shares — an estimated $111K sold.

Jeff Yass first reported a position in CARM in Q2 2015 and held it in 26 quarters. The position peaked at $3.61M in Q2 2021. 37 funds tracked by Wall St. Rank hold CARM as of Q3 2024.

  • Jeff Yass reported no remaining Carisma Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jeff Yass sold 73,323 Carisma Therapeutics shares in Q3 2024, an estimated $111K.
  • Jeff Yass first reported a position in Carisma Therapeutics in Q2 2015 and held it in 26 quarters.
  • Jeff Yass's Carisma Therapeutics position peaked at $3.61M in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.